Tweetable abstract Pretreatment UGT1A1 genotyping and a 70% irinotecan dose intensity in poor metabolizers is safe, feasible, cost-effective and essential for safe irinotecan treatment in cancer patients. It is time to update guidelines to swiftly enable the implementation of UGT1A1 genotype-guided irinotecan dosing in routine oncology care.
Keywords: PGx; UGT1A1; irinotecan; personalized medicine; pharmacogenetics; pharmacogenomics; precision dosing; pretreatment.